← Evidence map

ArticleGene therapy2026

Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected cases.

Philipp Berg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

7 papers cite it

2026

this papercites it

Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected cases. | OpenQuestion